-
Machine Learning-Guided LNPs for Microglial mRNA
2026-09-21
Rafiei, Shojaei, and Chau developed a machine learning-assisted workflow to design lipid nanoparticles that deliver mRNA to inflammatory microglia and alter their phenotype. The study links formulation variables, transfection performance, and cell morphology, identifying HA-LNP2 as a promising carrier for IL10 mRNA in cellular models of microglial hyperactivation.
-
N-Formimidoyl Thienamycin vs New β-Lactams
2026-09-21
This 1982 comparative study evaluated N-formimidoyl thienamycin (MK0787) against resistant clinical isolates and several newly developed β-lactams. Its main contribution was to show unusually broad, β-lactamase-independent activity, particularly against Pseudomonas aeruginosa and Acinetobacter spp., while also defining organism-specific differences from cefotaxime and moxalactam.
-
Mouse IL-7 mRNA for Glial–Vascular Assays
2026-09-20
Build a controlled, transient IL-7 expression workflow for mouse glial, immune, and endothelial co-culture studies. The HA tag enables translation tracking, while a reference-informed assay framework connects glial activation to vascular readouts without overstating what the product has been validated to do.
-
In Vitro Drug Response Metrics in Cancer Research
2026-09-19
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated measurements capture different relationships between growth inhibition and cell death. The findings support endpoint-aware experimental design and caution against interpreting a single viability value as a direct measure of cytotoxicity.
-
Roscovitine: Linking CDK Arrest to Immune Assays
2026-09-18
Roscovitine (Seliciclib) is a reversible, multi-CDK perturbation tool for connecting tumor cell-cycle state with immune-enabled cancer biology research. This guide translates its late-prophase activity and in vivo evidence into assay decisions informed by recent radiotherapy and checkpoint-blockade findings.
-
EZ Cap™ CPF1/Cas12a mRNA: Assay Logic
2026-09-18
Explore how EZ Cap™ CPF1/Cas12a mRNA (m1Ψ) can be evaluated as a transient Cas12a expression component through an assay-first framework. This article connects Cpf1 engineering evidence with target selection, controls, readout strategy, and scientifically cautious interpretation.
-
7ACC2: MCT1 Inhibitor for Cancer Metabolism
2026-09-17
7ACC2 enables controlled interrogation of lactate uptake, mitochondrial pyruvate handling, and metabolic stress in tumor models. Its nanomolar activity and reported radiosensitizing profile make it useful for cancer metabolism research, while the 25-hydroxycholesterol–macrophage findings suggest a carefully bounded route into immunometabolic assay design.
-
Hoechst 33342/PI Double Staining Kit Workflow
2026-09-17
Use the Hoechst 33342/PI Double Staining Kit to distinguish chromatin condensation from loss of membrane integrity in drug-treated cells. This practical workflow adapts the syringin–sunitinib renal cell carcinoma study into a rapid fluorescent apoptosis assay with clear controls, imaging guidance, and troubleshooting steps.
-
D-Lin-MC3-DMA for Reliable RNA Assays
2026-09-16
Learn how D-Lin-MC3-DMA (SKU A8791) can improve the interpretation of cell viability, proliferation, and cytotoxicity assays used to evaluate siRNA and mRNA delivery. This scenario-based guide connects ionizable lipid chemistry, formulation parameters, controls, storage, and literature-backed LNP performance.
-
Hippo Signaling in Hepatobiliary Maturation
2026-09-16
This preprint identifies HPO1 and HPO2 as spatiotemporally distinct Hippo pathway modules that coordinate hepatocyte and cholangiocyte maturation in mouse liver. Its findings reposition Hippo signaling from a general organ-size regulator to a set of developmental checkpoints that control cell identity, maturation, and survival.
-
CLK2, BRCA1, and Platinum Resistance in Ovarian Cancer
2026-09-15
A 2024 study identifies CLK2 as a mechanistic driver of platinum resistance in ovarian cancer, linking CLK2-dependent BRCA1 Ser1423 phosphorylation to enhanced DNA damage repair. Its tissue, cellular, and xenograft evidence supports CLK2 as a candidate therapeutic target while also defining important limits for translating family-level kinase inhibition into CLK2-specific conclusions.
-
IDH2, Ferroptosis, and TNBC Proliferation
2026-09-15
A 2024 Scientific Reports study identifies wild-type IDH2 as a ferroptosis-associated regulator of triple-negative breast cancer proliferation. By combining tumor-data analysis, clinical validation, cell experiments, and mouse models, the authors connect elevated IDH2 with reduced ferroptotic susceptibility and more aggressive tumor behavior.
-
RapaLink-1: Reframing mTOR Inhibition for Translation
2026-09-14
RapaLink-1, a third-generation mTOR inhibitor, illustrates how bivalent pathway engagement can address resistance while creating a stronger framework for translational research. By connecting oncology data with emerging mTOR-based embryonic dormancy protocols, this article outlines practical validation strategies, experimental parameters, and the limitations that should guide future work.
-
Netarsudil: From ROCK Inhibitor to RNA Assay Design
2026-09-14
Netarsudil (AR-13324) is more than a selective ROCK inhibitor: it is a useful model for connecting trabecular meshwork biology with rational siRNA formulation. This guide explains how to separate direct cytoskeletal effects from nanoparticle-enabled gene silencing in rigorous assay design.
-
Troglitazone as a PPARγ Agonist in TAM Assays
2026-09-13
Troglitazone provides a practical way to test how PPAR-driven metabolic signaling influences macrophage state, SPP1 biology, and tumor-cell responses. This workflow separates established receptor pharmacology from the emerging tumor-associated macrophage opportunity identified by phenotypic screening.